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ABSTRACT 
 A common practice amongst street drug manufacturers and dealers is to 
combine the illicit drug of abuse they intend to distribute with additional substances.  
Substances added in an attempt to mimic or enhance the desired effect of the drug of 
abuse are known as adulterants as opposed to diluents, which are added simply to 
increase the weight of the product.  By definition, an adulterant has a physiological 
effect on the body and as physiologically active compounds these adulterants may 
have side effects apart from the drug it is added to.  They can be minimal, treatable, 
or otherwise manageable while others can be worse than those incurred from the 
drug of abuse itself.  
Due to varying trends in street drug purity, an effort must be made to 
understand the effects adulterants and diluents, as well as mixtures thereof, may have 
on forensic drug analysis.  Colorimetric spot test analysis is typically performed using 
a representative sample of the raw, suspected drug material.  These tests are often 
employed in the lab prior to any attempt to isolate a specific compound or at the 
scene before an arrest is made.  This being the case, the reagents will be exposed to 
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and have the potential to react with anything present in the sample with the drug of 
abuse.  While much work has been done regarding the specificity and cross reactivity 
of colorimetric spot tests, limited information is available about how mixtures of 
adulterants may affect the results. 
This research consists of two parts which approach the common theme of 
adulterants differently. The first part is a literature based investigation into the 
pathological side effects of several common drug adulterants.  The specific 
compounds discussed are:  levamisole, phenacetin, atropine, and several topical 
anesthetics (benzocaine, lidocaine, prilocaine, and procaine).  A review of articles 
from the scientific literature was conducted in order to convey what is known in the 
medical field regarding the effects these compounds can have on the body. The 
second part of this research was a laboratory based investigation which analyzed the 
effects of twenty-three common adulterants on two colorimetric spot tests: the 
Marquis reagent for the presumptive identification of heroin, morphine, 
amphetamine, methamphetamine, and 3,4-methylenedioxy-N-methamphetamine 
(MDMA) and the modified Scott test for the presumptive identification of cocaine. 
This was performed in order to observe the reactivity of these compounds so that a 
better understanding of the effect their presence can have on the analysis of seized 
drug samples using these tests could be obtained. 
The literature review portion of this research revealed that the adulterants 
levamisole, atropine, phenacetin, and the topical anesthetic adulterants lidocaine, 
prilocaine, benzocaine, and procaine, can be toxic and have severe, deleterious 
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effects on the body in both chronic and acute exposures. Levamisole stimulates the 
immune system resulting in the production of self-reactive antibodies that attack 
neutrophils. This causes an autoimmune disorder that weakens the immune system 
and causes leukocyte agglutination leading to necrotizing vasculitis. Atropine 
functions to decrease the parasympathetic tone and increase the sympathetic tone in 
the body.  An overdose can cause anticholinergic toxicity, a syndrome very similar to 
sympathomimetic toxidrome caused by cocaine overdose. Both are characterized by 
hypertension, hyperthermia, tachycardia, ataxia, disorientation, and mydriasis. 
However, they can be distinguished as anticholinergic toxicity causes dry and flush 
skin and mydriasis which is unreactive to light while sympathomimetic toxidrome 
causes profuse sweating and mydriasis which is reactive to light.  Phenacetin is 
metabolized to O-ethyl-N-acetyl-p-benzoquinone imine (O-Et-NAPQI), a highly 
reactive and unstable electrophile. It is capable of covalently binding with proteins 
and other cellular components, including deoxyribonucleic acid (DNA). This leads 
to mutagenesis and subsequent tumor generation as well as apoptosis and necrosis of 
various tissues in the bladder and kidneys.  The topical anesthetics have each been 
associated with the development of methemoglobinemia.  This is a condition caused 
by an increase in the concentration of methemoglobin in the blood. Methemoglobin 
binds more strongly to oxygen so that it cannot be released to the tissues resulting in 
oxygen starvation.  This was found to be caused by the metabolism of prilocaine and 
lidocaine to the oxidative compounds O-toluidine and 2,6-xylidine respectively. The 
cause has not been previously reported for benzocaine or procaine. 
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The laboratory portion of this research revealed the impact several adulterants 
and their mixtures can have on colorimetric spot tests.  Testing with approximately 1 
mg of sample material revealed that eight out of the twenty-three adulterants reacted 
with the Marquis reagent to cause a color change within 15 minutes.  Of the ten 3-
component mixtures tested, eight resulted in a color change.  Of the six five-
component mixtures, four resulted in a color change; of the six eight-component 
mixtures, three resulted in a color change; and of the six ten-component mixtures, 
five resulted in a color change.  Of the color changes observed, none were consistent 
with the ―expected‖ color change for a presumptively positive result of the Marquis 
test.   
Testing with the adulterant diphenhydramine revealed that this compound 
had a unique and intense reaction with the Marquis reagent. This compound initially 
reacted by turning the liquid a vibrant yellow-green upon contact with the sample. 
Prior to 2 minutes, solid red-brown aggregates formed in the liquid and proceeded to 
increase in size while the reagent solution darkened to a red-black color over the 15 
minutes of observation.  Mixtures containing diphenhydramine each reacted 
differently. Solid material did not form in the mixture tests and the color changes 
observed ranged from light orange to a dark red-orange.  In addition, one 3-
component mixture containing adulterants which did not cause a color change when 
tested individually (diltiazem, acetaminophen, and quinine) was observed to cause a 
light brown color to develop, which darkened over the 15 minutes of observation.   
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The results for the modified Scott test showed that the complexity of this test 
has made it highly specific for cocaine. None of the individual components or 
mixtures tested reacted in a manner consistent with a presumptively positive 
identification for cocaine hydrochloride (HCl) or cocaine base for all three steps. Of 
the twenty-three adulterants tested, eight of the twenty-three gave a similar result to 
cocaine base in step 1, however, of these eight, only one (quinine) gave a similar 
result to cocaine base in step 2, and this adulterant did not react consistently to 
cocaine base in step 3. The research using the adulterant mixtures revealed that the 
compounds present in these samples tended to react individually with the modified 
Scott test reagents.  In other words, the results for each mixture appeared as a 
combination of the individual results for each component.  
While the results observed for the adulterants and mixtures tested were not 
consistent with the expected presumptively positive results for the drugs these tests 
are used to detect, it was concluded that the presence of adulterants in a sample has 
the potential to affect the results of a colorimetric spot test in a variety of ways.  
Given that these tests are typically employed on samples of raw suspected drug 
material, it is important that analysts understand the impact adulterants can have on 
the interpretation of presumptive drug tests. 
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1. INTRODUCTION 
1.1 Adulterants 
A common practice among street drug manufacturers and dealers is to 
combine the illicit drug of abuse they intend to distribute with additional substances.  
This allows them to sell less of the illicit substance for the same price.  Substances 
added in an attempt to mimic or enhance the desired effect of the drug of abuse are 
known as adulterants as opposed to diluents, which are added simply to increase the 
weight of the product.  An example of an adulterant would be caffeine added to a 
sample of cocaine.  The caffeine’s stimulating effect on the body would mimic that of 
cocaine, causing the user to feel as though they have consumed a high-purity cocaine 
sample when they have not.  In this way, the manufacturer or dealer will be able to 
sell less cocaine, which is valuable and expensive, and more caffeine, which is 
common and cheap, while their ―customers‖ believe they are getting a high quality 
product.  An example of a diluent would be baking soda added to cocaine.  The 
baking soda has no physiological effect on the body; however, it mimics cocaine in 
its appearance.  The dealer or manufacturer would add baking soda to their product 
in order to increase the weight, or ―dilute‖ the cocaine.  This accomplishes the same 
goal of increasing the volume available for distribution, but is more obvious to the 
buyer as they may perceive a lack of potency since more of the substance may be 
required to achieve the desired effects of the drug. 
In forensic casework, the adulterants present in seized drug samples are often 
overlooked or ignored during analysis.  However, adulterants themselves can have 
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an effect on various aspects of a forensic investigation; from presumptive drug 
identification at the scene to the forensic pathologist’s autopsy.  In this thesis, I will 
discuss the damaging physiological effects certain adulterants can have on the body.  
In addition, the effects of twenty-three different adulterants commonly found in 
heroin and cocaine on two colorimetric spot tests will be explored.  The twenty-three 
adulterants investigated in this study are shown in Figure 1 along with their chemical 
structures. 
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Figure 1:  Chemical structures of the 23 adulterants tested.  
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1.2 Forensic Pathology and Drug Adulterants 
 By definition, a drug adulterant has a physiological effect on the body.  It is 
typical for this effect to either enhance or emulate an effect of the drug of abuse (1). 
For example, lidocaine is often added to cocaine to mimic the anesthetic effect the 
drug has on the lips and gums and is added to heroin in order to ease the pain of 
injection by numbing the injection point locally (1). Acetaminophen is often added to 
heroin due to the analgesic properties they share, and sedatives such as xylazine and 
phenobarbital are added which mimic the tranquilizing effect of this drug (1). As 
physiologically active compounds, these adulterants may come with their own side 
effects apart from the drug it is added to.  Some are minimal, treatable, or otherwise 
manageable, while others can be worse than those incurred from the drug of abuse 
itself.   
 Here, several examples of adulterants and their side effects will be discussed.  
The specific compounds are: levamisole, phenacetin, atropine, and the topical 
anesthetics: benzocaine, lidocaine, prilocaine, and procaine.  A review of articles 
from the scientific literature will be conducted in order to convey what is known in 
the medical field regarding the effects these compounds can have on the body and a 
synopsis of the pathology will be provided with an emphasis on the forensic 
pathology and application to death investigation.  This topic will be approached by 
first asking a question based on the structure or mechanism of action of the 
adulterant and what kind of side effects one might see as a result of the consumption 
of these compounds.  Literature research will be performed to determine if these 
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effects are indeed observed, and finally, the information will be applied to forensic 
pathology and death investigation.  Physical observations, which may be made 
during autopsy and/or notable findings in a decedent’s medical history, will be 
presented which may alert the forensic pathologist or death investigator to the 
incidence of exposure to these compounds. 
 While the forensic medicine and pathology considerations differ from those of 
forensic chemistry, they are both affected by the presence of adulterants.  In both 
fields, adulterants can cause interpretive problems that the analyst must be aware of.  
The research done in this thesis highlights the common theme of adulterants and the 
difficulties they can cause throughout a forensic investigation using two different 
approaches to the same topic. 
1.3 Colorimetric Spot Tests 
 Colorimetric spot tests are used in forensic casework in order to quickly 
screen a sample prior to more discriminating tests.  Using a spot test or a series of 
spot tests, an analyst can determine whether or not a certain drug of abuse may be 
present.  This allows the analyst to make an educated decision moving forward in 
their analysis.  With a limited amount of sample, the analyst can determine if it will 
be of interest to the case or not and thus, if any further testing needs to be done.  
These tests are only preliminary tests, which tell the analyst a certain drug may be 
present.  If a colorimetric spot test indicates that a drug may be present, the analyst 
will follow this test with a confirmatory technique such as gas chromatography/mass 
spectrometry (GC/MS) analysis.  If presumptive analysis does not indicate that a 
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drug may be present, the analyst would make an educated decision about whether or 
not further testing is required, potentially saving the forensic laboratory time and 
money by avoiding expensive and unnecessary testing. 
 The Scientific Working Group for the Analysis of Seized Drugs 
(SWGDRUG) has put forth a series of recommendations for the analysis of drug 
samples (2).  The SWGDRUG recommendations divide the analytical techniques 
used in forensic chemistry into categories based on their potential discriminating 
power.  The categories are:  A (most discriminating), B, and C (least discriminating).  
The categories and their techniques are listed in Table 1.   
Table 1:  SWGDRUG categories of analytical techniques.  
Category A Category B Category C 
Infrared Spectroscopy Capillary Electrophoresis Color Tests 
Mass Spectrometry Gas Chromatography 
Fluorescence 
Spectroscopy 
Nuclear Magnetic 
Resonance 
Spectroscopy 
Ion Mobility 
Spectrometry Immunoassay 
Ramen Spectroscopy Liquid Chromatography Melting Point 
X-Ray Diffractometry Microcrystalline Tests 
Ultraviolet 
Spectroscopy 
  Pharmaceutical Identifiers   
  
Thin Layer 
Chromatography   
  
Macroscopic and/or 
Microscopic Examination 
(Cannabis only)   
 
The SWGDRUG recommendations state that a laboratory’s minimum 
standard for identification should include analysis using a validated category A 
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technique and at least one other technique from either category A, B, or C (2).  If a 
category A technique is not used, then at least three different validated techniques 
should be used with at least two of the three being from category B (2).  Colorimetric 
spot tests are among the category C analytical techniques and are typically employed 
as a precursor to more discriminating analysis.  When presumptive identification 
with a color test has been completed, the analyst will then proceed to a category A or 
B technique to confirm the results. 
Typically, a presumptive color test is most useful when it is quick, sensitive, 
and specific.  The sensitivity is the limit of detection for a certain drug by a given test.  
The National Institute of Justice (NIJ) Standard 0604.01:  Color Test Reagents/Kits 
for Preliminary Identification of Drugs of Abuse states that a color test’s limit of 
detection is to be defined as ten times the lowest quantity at which a color change 
occurs five out of five times (3).  This lower limit is important as forensic laboratory 
equipment such as GC/MS, which are typically used in drug analysis, have 
considerably lower limits of detection.  This means that a presumptive test may not 
indicate the presence of a compound of interest that a more sensitive instrument may 
be able to detect.  Confirmatory instruments used in the lab are costly and time 
consuming.  A presumptive test with a high degree of sensitivity will allow for the 
detection of illicit substances in lower quantities, which can then be used to more 
accurately inform the next step in analysis.  
One limitation of colorimetric spot tests is a lack of specificity.  Specificity 
describes the potential for a given test to cross react with multiple compounds 
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arriving at a similar result as expected for the targeted compound (3).  The lack of 
specificity of spot tests is due to the fact that the reactions which occur are not 
specific to one compound; rather they occur as a result of the reagent(s) reacting with 
certain functional groups on a molecule (4).  Often, though not always, the observed 
color change is the result of a rapid organic synthesis reaction between the reagent(s) 
in the test and the drug molecule in the sample forming a colored product.  
Molecules containing the same functional group, or another functional group 
reactive to the reagent, have the potential to undergo a similar reaction resulting in a 
colored product as well.  This product may or may not exhibit a color similar to 
those of the target drug molecule.  A preliminary color test should have a high degree 
of specificity.  This allows for more targeted testing and more informative 
preliminary identification.  The NIJ Standard 0604.01 states that a differentiation 
occurs when the final color observed from a compound reacted with a test is not in 
the vicinity of the colors observed from other compounds using the same test (3).  In 
addition, differentiation can be arrived at using multiple tests on the same sample; 
however, this requires more sample consumption and time.  A test with a high 
degree of sensitivity and specificity can streamline analysis and allow the analyst to 
make informed decisions when moving forward with their identification. 
The most significant limitation of colorimetric spot tests lies within their 
reliance on the interpretation of a subjective, qualitative result, i.e. color.  The 
interpretation of these tests is not typically performed with any machine or 
instrument that will give a quantitative value to the color produced by the reaction.  
9 
The results are only interpreted visually by the analyst.  This makes the results reliant 
on an individual’s definition of color, which may be different from another’s.  The 
laboratory portion of this research will show how the presence of adulterants can 
affect the outcome of a test in ways that can make them increasingly difficult to 
interpret.  
Due to varying trends in street drug purity, an effort must be made to 
understand the effects adulterants and diluents, as well as mixtures thereof, may have 
on presumptive drug tests.  Colorimetric spot test analysis is typically performed 
using a representative sample of the raw suspected drug material.  These tests are 
often employed in the lab before any attempt to isolate a target molecule, or at the 
scene before an arrest is made.  This being the case, the reagents will be exposed to 
and have the potential to react with anything present in the sample with the drug of 
abuse.  While much work has been done regarding the specificity and cross reactivity 
of colorimetric spot tests, a thorough search was performed and no information was 
found regarding how mixtures of adulterants may affect the results.  In this study, the 
reactions of twenty-three common adulterants, and mixtures thereof, with two 
colorimetric spot tests were observed.  The two tests used were the Marquis reagent 
and the modified Scott test. 
1.3.1 Marquis Reagent 
 The Marquis reagent is a 0.05:1 solution of 40% formaldehyde (in water) and 
concentrated sulfuric acid (5).  It is a versatile test and, according to the general 
testing protocol recommended by the Narcotics Analysis Identification Kit (NARK®) 
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presumptive tests that are frequently used by law enforcement, it is the first of the 
presumptive tests done on an unknown substance (6).  This test can be used to 
presumptively identify the presence of heroin and morphine, 3,4-methylenedioxy-
methamphetamine (MDMA), and amphetamines (7).  The NIJ Standard 0604.01 
has the official limit of detection for these drugs listed as 10 micrograms (µg) and 5 
µg for amphetamine and methamphetamine respectively, 10 µg and 5 µg for heroin 
and morphine respectively, and the limit of detection for MDMA is unlisted (3).  
Heroin and morphine are presumptively identified by the development of an orange 
color which changes to purple while MDMA is presumptively identified by an 
orange color which changes to black.  An orange color which changes to brown 
within 12 seconds indicates the possible presence of an amphetamine; however, 
additional tests are required to distinguish between amphetamine and 
methamphetamine (6).  If the results indicate the possible presence of amphetamines, 
the analyst may follow up with the sodium nitroprusside reagent (also known as the 
Simon test) (6,8).  This test can distinguish between amphetamine and 
methamphetamine.  If the test indicates the possible presence of heroin or morphine, 
the sample may be tested further using the nitric acid test which can distinguish 
between the two (6).  Additionally, the Marquis test is known to not cross react with 
cocaine.  Therefore a lack of a color development from this test is informative to the 
analyst as well.  If no color change occurs, it is suggested that the sample be tested 
next using the modified Scott test for the presumptive identification of cocaine (6). 
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1.3.2 Modified Scott Reagent 
 The modified Scott test is used for the preliminary identification of cocaine.  
This test is a modified version of the cobalt thiocyanate test.  The cobalt thiocyanate 
test was previously used for the identification of cocaine, however, it was susceptible 
to ―false positives‖ as other controlled substances such as methaqualone, 
phencyclidine, and heroin also yield a positive result (9).  This test was modified by 
L. J. Scott in 1973 to make the test more specific to cocaine and then further 
modified in 1986 by J. Fansello and P. Higgins to make the test applicable to both 
cocaine hydrochloride (HCl) and cocaine base (9).  The modified Scott test requires 
the application of three different reagents in a specific order.  The first step is a 
solution of 2% cobalt (II) thiocyanate in a 1:1 solution of 10% acetic acid and 
glycerin, the second step is the addition of concentrated hydrochloric acid, and the 
third step is an extraction with chloroform (7).  Figure 2 shows the progression of a 
positive result for cocaine base and cocaine HCl.  As shown, if a sample contains 
cocaine base, the sample material will not dissolve but will turn blue during the first 
step; during the second step the solution will remain pink, but the blue sample will 
dissolve; during the third step, two layers will form: the top, aqueous, layer will be 
pink while the bottom, organic, layer will be blue.  If the sample being tested is 
cocaine HCl, the sample will dissolve and the pink reagent solution will turn blue in 
the first step; during the second step, the blue solution will change back to pink; and 
during the third step, again, two layers will form with the pink aqueous layer over the 
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blue organic layer (7).  The drug detection limit is listed as 60 µg for cocaine in the 
NIST Standard 0604.01 (3). 
 
Figure 2:  Flow chart depicting the expected results for the modified Scott test.  
 
2. MATERIALS AND METHODS 
2.1 Materials 
 Each colorimetric spot test was performed using a NARK® II reagent kit 
(Sirchie Fingerprint Laboratories, Youngsville North Carolina) obtained from 
Evident® Crime Scene Products.  These tests include:  Marquis Reagent 
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(NARK®2001) and the Modified Scott Reagent (NARK®2007).  Any methanol used 
as a solvent was obtained from Fisher Scientific© (99.9% purity).  The various 
adulterants tested were obtained from several different manufacturers.  Atropine free 
base, procaine, lidocaine, tetramisole HCl, xylazine HCl, levamisole HCl, piracetam, 
and hydroxyzine dihydrochloride (2HCl) were obtained from MP Biomedicals, 
Limited Liability Company (LLC)©.  Acetylsalicylic acid, creatine monohydrate, 
diphenhydramine HCl, thiamine HCl, and inositol were obtained from Acros 
Organics©.  Acetaminophen, creatinine, and quinine were obtained from Sigma-
Aldrich®.  Phenacetin and diltiazem were obtained from Santa Cruz Biotechnology©.  
Mannitol and caffeine were obtained from Fisher Scientific©.  Benzocaine was 
obtained from Chem-Service© and prilocaine HCl was obtained from Alfa Aesar©.  A 
phenobarbital standard was acquired as a 1 mg/mL solution in methanol from 
Cerilliant©.  Any adulterant requiring refrigeration as suggested by the manufacturer 
as well as any mixture containing such an adulterant were stored in a refrigerator at 
approximately 3° Celsius (C). 
 Additional materials used included:  disposable transfer pipettes, 5 milliliter 
(mL) black screw-top vials, 100 mL white screw-top vials, stainless steel transfer 
spatulas, tweezers, weighing paper, ceramic crucibles, a 3x4 white porcelain spot 
plate, glass test tubes, test tube rack, and a digital analytical scale manufactured by 
Denver Instruments®.  
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2.2 Mixture Rationale 
 The purpose of creating and testing mixtures of adulterants is based on the 
notorious impurity of street drug samples.  The bulk samples may be adulterated at 
the manufacturer level and subsequently adulterated further each time it is 
transferred to a new buyer; which may occur multiple times before reaching the end 
user.  Whenever the drug is prepared for distribution there is the potential to increase 
profit by cutting it with adulterants.  The dealers or distributors of street drugs will 
add what substances are available to them.  The preparation of larger mixtures of 
adulterants in this research is an attempt to recreate the end-level impurity of drugs of 
abuse and evaluate the effects of more complex chemical mixtures. 
 The specific combinations of adulterants used in each mixture were based on 
the properties of the adulterant and the effects it can have on the body.  For example: 
a mixture of caffeine, benzocaine, and procaine was tested because caffeine is a 
stimulant and benzocaine and procaine are topical anesthetics therefore this 
combination may be found in street samples of cocaine. Likewise, a combination of 
hydroxyzine, diltiazem, and lidocaine was tested to simulate a mixture, which could 
possibly be found in heroin since hydroxyzine and diltiazem are depressants and 
lidocaine is a topical anesthetic. This rationale was continued into the larger 
mixtures. For example a five-component mixture consisting of the analgesics 
acetaminophen, acetylsalicylic acid, and piracetam, as well as the sedative xylazine, 
and the commonly encountered adulterant levamisole was tested to simulate a 
possible combination of adulterants found in a real-world sample of heroin.  The 
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most common compounds used in the creation of these mixtures were lidocaine and 
levamisole.  This is due to the fact that both are known to be very common 
adulterants in cocaine and have been reportedly found in heroin as well (1,10,11).  
2.2.1 Mixture Preparation 
Prior to the preparation of the mixtures to be tested, an organizational system 
was developed to maintain consistency and clarity for each mixture composition.  
First, the common names of each of the twenty-three adulterants were organized in 
alphabetical order and assigned a letter symbol (A-W).  Next, a numbering system 
was developed for the mixtures.  This numbering system indicated the number of 
compounds present in the mixture followed by a period followed by a randomly 
assigned number for that mixture in sequence (i.e.: 3.01 is mixture number one of the 
3-component mixture set).  This information is organized in Table 2. 
To prepare the mixtures of the three-component samples, approximately 100 
milligrams (mg) of each of the three components were weighed out on a piece of 
weighing paper using a digital analytical scale.  The weighed sample was then added 
to a ceramic crucible and the mixture was homogenized using the crucible as a 
mortar and a glass test tube as a disposable pestle.  The mixture was homogenized 
for approximately five minutes, then collected and added to a labeled white top vial 
for later use.  This process was repeated for each of the ten, 3-component samples 
(Table 2). 
To prepare the mixtures of the five-component samples, the above process 
was repeated for mixtures 5.2, 5.3, and 5.4.  However, due to a limited supply of 
16 
certain adulterant components used in mixtures 5.1, 5.5, and 5.6, only 50 mg of each 
component present in these mixtures were used.  
To prepare the mixtures of the eight-component samples, a combination of 
the three and five component samples prepared previously was done.  12 mg of the 
three-component mixture and 20 mg of the five-component mixture were weighed 
out and homogenized using the method described previously.  This ensured that each 
component was present in an approximately one-eighth proportion.  The ten-
component mixtures were prepared in a similar manner, using a combination of 20 
mg of two different five-component mixtures.  Each mixture used was chosen so that 
no single component was redundant (i.e. not present in both mixtures) (Table 2). 
17 
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2.3 Procedures for Spot Test Examinations 
 The spot test examinations performed were completed using the NARK® II 
Marquis reagent and modified Scott test kits, however, the procedures recommended 
by the manufacturer, intended for field use, were adapted to fit the precision afforded 
by a laboratory setting (6).  Each test was performed using approximately 1 mg of 
sample material weighed on a digital analytical scale on a piece of weighing paper.  
The testing pouch was opened and the vial harness was removed using tweezers 
prior to the addition of the sample.  The sample was then added to the pouch and the 
bottom of the pouch was tapped on the lab bench while the top of the pouch was 
covered.  This, as well as the removal of the vial harness, was done to ensure the 
maximum amount of sample was allowed to reach the bottom of the pouch.  Once 
the sample was in the pouch and tapped along the bottom, the vial harness was 
replaced and the pouch was re-sealed with the clip provided.   
For the Marquis reagent, the vial was broken and the pouch was agitated for 
two to three seconds while a stopwatch was started.  The pouch was then propped up 
vertically and observed for 15 minutes.  The results were photographed and notes 
were taken at the two, five, ten, and fifteen-minute intervals.  The test pouch was 
agitated prior to each photograph.  For the modified Scott reagent, the vials were 
broken in the correct sequence.  After each vial was broken, the pouch was agitated 
for two to three seconds then observed for two minutes and photographed.  Each 
adulterant was first tested individually, then mixtures of increasing complexity were 
analyzed.  
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 Due to a very limited supply of phenobarbital, the tests were performed using 
a different technique.  For this adulterant, 50 microliters (µL) of a 1 mg/mL solution 
in methanol was added to a white porcelain spot plate for testing via the Marquis 
reagent and a glass test tube for testing via the modified Scott reagent.  The methanol 
was then allowed to evaporate to dryness in a fume hood.  The reagent chemicals 
were obtained by removing the vial harness from the testing pouch and breaking the 
vials into separate, labeled, white screw-top glass vials.  For the Marquis reagent, ten 
drops of the reagent were added to the spot plate using a transfer pipette and the 
results were observed and photographed.  For the modified Scott reagent, five drops 
were added from vial one (cobalt thiocyanate solution), two drops were added from 
vial two (hydrochloric acid), and ten drops were added from vial three (chloroform) 
using a transfer pipette.  The sample was then monitored and photographed. 
3.  RESULTS 
3.1 Color Changes Observed During Testing with the Marquis Reagent 
 Testing with approximately 1 mg of each of the twenty-three adulterants 
individually revealed that eight out of the twenty-three adulterants reacted with the 
Marquis reagent to cause a color change (Table 3).  The remaining fifteen adulterants 
either did not cause a color change within 15 minutes, or the first visualization of a 
color change did not occur until 15 minutes after exposure to the reagent.  
Adulterants in the latter category were not included because presumptive color tests 
are intended to be used as rapid screening techniques.  A color development after 15 
minutes is far too long to be considered practical.  In practice, the test would be 
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considered negative or inconclusive before this color change would be observed.  
There were no adulterants which gave a reaction that would mimic an expected 
positive result for any of the drugs that can be presumptively identified using the 
Marquis reagent.  
 
Table 3:  Summary of Marquis results for single adulterant samples.  A (+) 
indicates a color change occurred and a (—) indicates a color change did not occur.  
 
Adulterant 
Color 
Change 
(+/—) Adulterant 
Color 
Change 
(+/—) Adulterant 
Color 
Change 
(+/—) 
Acetaminophen — Inositol — Tetramisole  + 
Acetylsalicylic 
Acid  + Levamisole  + 
Thiamine 
HCl — 
Atropine  + Lidocaine  + Xylazine HCl — 
Benzocaine — Mannitol — 
  
Caffeine — Phenacetin — 
Creatine 
Monohydrate — Phenobarbital* — 
Creatinine — Piracetam — 
Diltiazem — Prilocaine HCl  + 
Diphenhydramine  + Procaine — 
Hydroxyzine 
2HCl  + Quinine — 
 
*The absence of a color change from phenobarbital could also be due to the lower 
concentration this adulterant was tested at rather than a lack of reactivity with the 
Marquis reagent.  
 
The reactivity of each adulterant which elicited a color change varied in 
intensity.  For example:  acetylsalicylic acid did not display a color change until 5 
minutes after exposure when a faint pink-orange color was visible.  The intensity of 
the color increased over time and the color appeared more saturated by 15 minutes.  
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Other adulterants such as diphenhydramine and atropine displayed a color change 
either immediately or within 30 seconds of exposure and developed quite differently 
over the 15 minutes of observation.  These results are summarized in Table 4. 
 
Table 4:  Table showing colors observed over 15 minutes of observation for each 
adulterant which displayed a color change.  A (—) indicates that no color change 
was observed at that time interval.   
 
Adulterant 2 minutes 5 minutes 10 minutes 15 minutes 
Acetlysalicylic Acid —       
Atropine         
Diphenhydramine*         
Hydroxyzine         
Levamisole         
Lidocaine         
Prilocaine         
Tetramisole         
 
Note:  Colors depicted are approximations; the actual colors observed may appear 
different in hue and/or saturation.  
*Diphenhydramine had a unique reaction in that, in addition to the immediate 
development of a yellow-green and subsequently red-orange to red-black color, the 
development of red solid material within the solution was also observed.  
 
Of the ten, 3-component mixtures tested, eight resulted in a color change 
within 15 minutes.  Of the six, five-component mixtures, four resulted in a color 
change; of the six, eight-component mixtures, three resulted in a color change; and of 
the six, ten-component mixtures, five resulted in a color change (Tables 5&6).  
Again, of the color changes observed, none of the mixtures resulted in a color change 
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which resembled an expected positive result for any of the drugs presumptively 
identified using the Marquis reagent.   
Table 5: Summary of Marquis results for 3-component mixtures.  A (+) indicates a 
color change occurred and a (—) indicates a color change did not occur.  (A = 
Acetaminophen, B = Acetylsalicylic Acid, D = Benzocaine, E = Caffeine, F = 
Creatine Monohydrate, H = Diltiazem, I = Diphenhydramine, J = Hydroxyzine, K 
= Inositol, L = Levamisole, M = Lidocaine, N = Mannitol, R = Prilocaine, S = 
Procaine, T = Quinine, U = Tetramisole) 
 
Mixture Components 
Color 
Change 
(+/—) 
3.01 AHT  + 
3.02 BIU  + 
3.03 BLM  + 
3.04 DES — 
3.05 FKN — 
3.06 FLN  + 
3.07 HJM  + 
3.08 IJM  + 
3.09 ILM  + 
3.10 LMR  + 
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 Many of the mixtures resulted in somewhat expected color changes that 
appeared as a combination of the color changes observed by their components.  For 
example:  mixture 3.10 (levamisole, lidocaine, and prilocaine) had an orange-brown 
final color.  This is somewhat expected as levamisole reacted to turn brown while 
prilocaine and lidocaine both reacted to turn pink-red.  The final color appeared as 
an orange-brown combination of the three component colors.  However, mixture 
3.01 consisting of acetaminophen, diltiazem, and quinine had an unexpected 
outcome.  The three components individually did not cause a color change to occur 
within 15 minutes, however, the mixture resulted in a light-brown color development 
within 2 minutes which darkened over 15 minutes of observation (Figure 3).  In 
addition, mixtures containing diphenhydramine exhibited unique behavior which 
will be discussed more thoroughly below.  The colors observed from each mixture 
resulting in a color development are summarized in Table 7.  
 
Figure 3:  Results observed after 15 minutes for acetaminophen (top-left), 
diltiazem (center-left), and quinine (bottom-left) as well as mixture 3.01 (right) 
containing all three, when reacted with the Marquis reagent.  Each test was 
performed using approximately 1 mg of sample material.  
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Table 7:  Table showing colors observed over 15 minutes of observation for each 
adulterant mixture which displayed a color change.  A (—) indicates that no color change 
was observed.  (A = Acetaminophen, B = Acetylsalicylic Acid, C = Atropine, D = 
Benzocaine, E = Caffeine, F = Creatine Monohydrate, G = Creatinine, H = Diltiazem, I = 
Diphenhydramine, J = Hydroxyzine, K = Inositol, L = Levamisole, M = Lidocaine, N = 
Mannitol, O = Phenacetin, Q = Piracetam, R = Prilocaine, S = Procaine, T = Quinine, U = 
Tetramisole, V = Thiamine, W = Xylazine) 
Mixture Components 2 minutes 5 minutes 10 minutes 15 minutes 
3.01 AHT         
3.02 BIU         
3.03 BLM         
3.06 FLN —       
3.07 HJM         
3.08 IJM         
3.09 ILM         
3.10 LMR         
Mixture Components 2 minutes 5 minutes 10 minutes 15 minutes 
5.1 ABLQW         
5.2 BIJMU         
5.5 HJLMR         
5.6 CDRTV         
Mixture Components 2 minutes 5 minutes 10 minutes 15 minutes 
8.2 BLM & CDRTV         
8.3 DES & BIJMU         
8.4 BIU & HJLMR         
Mixture Components 2 minutes 5 minutes 10 minutes 15 minutes 
10.1 HJLMR & EGNOS —       
10.2 BIJMU & EGNOS         
10.3 BIJMU & CDRTV         
10.5 ABLQW & CDRTV —       
10.6 ABLQW & DFKTV —       
 
Note: Colors depicted are approximations. Actual colors observed may appear different in 
hue and/or saturation.   
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3.1.1 Unique Reactivity of Diphenhydramine with the Marquis Reagent 
 Of the twenty-three adulterants tested, the compound with the most intense 
reaction with the Marquis reagent was diphenhydramine.  Immediately following 
exposure to the Marquis reagent the 1 mg diphenhydramine sample dissolved and 
the liquid turned a bright yellow-green color.  Within 10 seconds, streaks of red solid 
material were observed forming throughout the liquid.  This red material continued 
to develop and formed larger aggregates which were suspended in the liquid.  By two 
minutes, the yellow-green liquid had darkened slightly and streaks of red material 
were visible throughout.  Additionally, deposits of the red material were visible 
above the meniscus of the liquid on the side of the testing pouch.  By 5 minutes the 
liquid had darkened further and become more of a dark red-orange color.  Large 
aggregates of solid material remained within the liquid.  By the 10 and 15-minute 
intervals the liquid had darkened to red-black.  The aggregates of red material were 
still visible within the liquid and on the sides of the pouch after 15 minutes (see 
Figure 4). 
27 
 
Figure 4: Diphenhydramine reaction over 15 minutes of observation. A) 30 
seconds B) 2 minutes C) 5 minutes D) 10 minutes E) 15 minutes after exposure to the 
Marquis reagent. 
  
The diphenhydramine reaction progressed differently when tested in 
combination with other adulterants.  The formation of red solid material was not 
observed in any mixture containing diphenhydramine.  Also, the color changes 
observed over 15 minutes varied among each mixture and were very different than 
the colors observed with diphenhydramine alone.  Mixture 3.02 displayed the color 
which was the most similar to diphenhydramine at 2 minutes, this being the yellow 
green liquid with red streaks throughout, however, it then developed a red-orange 
color by 5 minutes which eventually darkened to an orange-brown by 15 minutes.  
Mixture 3.08 began with the yellow-green color during the first 30 seconds; however 
this progressed to orange by 2 minutes and darkened to red-orange by 5 minutes then 
darkened further to red-black by 15 minutes.  The colors observed in mixtures 3.09 
and 5.2 were similar to those observed in 3.08 but darkened quicker.  These mixtures 
developed a red-orange color at two minutes then darkened to red-black by 10 
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minutes and were a very dark tar-black after 15 minutes.  Mixture 8.3 differed from 
8.4 as it appeared to have more of a green-brown color after 15 minutes while 8.4 
had more of an orange-brown color; however, they appeared very similar to one 
another.  Mixtures 10.2 and 10.3 were also similar to one another with 10.3 being 
slightly darker than 10.2.  Both of these mixtures reached a red-orange color by 2 
minutes which proceeded to darken to an orange-brown by 15 minutes.  The colors 
observed from 10.2 and 10.3 were closer to brown than black compared to those 
observed from previous mixtures.  Figure 5 shows the reactions observed from 
diphenhydramine in mixtures of increasing complexity. 
Figure 5:  Cropped photographs of Marquis reagent test results for 
diphenhydramine in mixtures of increasing complexity.  Mixture labels from top to 
bottom are:  3.02, 3.08, 3.09, 5.2, 8.3, 8.4, 10.2, and 10.3.  (B = Acetylsalicylic acid, 
C = Atropine, D = Benzocaine, E = Caffeine, G = Creatinine, H = Diltiazem, I = 
Diphenhydramine, J = Hydroxyzine, L = Levamisole, M = Lidocaine, N = 
Mannitol, O = Phenacetin, R = Prilocaine, S = Procaine, T = Quinine, U = 
Tetramisole, V = Thiamine) 
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3.2 Color Changes Observed During Testing with the Modified Scott Test 
 The results for the modified Scott test were quite variable among the fifty-one 
samples tested.  Of the individual adulterants and mixtures tested, the development 
of a blue color in the solvent was not observed during the first step.  There were, 
however, several tests, which resulted in blue flecks visible in the pink solution and 
several where the sample dissolved completely and the solvent remained pink.  For 
this reason, the results for the first step reported here will be regarding the color of 
any solid material visible rather than the color of the reagent solution, which was 
consistently pink.  The second step will be reported as the color of the reagent 
solution following the addition of hydrochloric acid and the third step will be 
reported as the color of the less dense, aqueous layer above the denser, organic layer.  
Of the twenty-three individual adulterants tested, eight of them resulted in the 
appearance of blue flecks during the first step.  This is consistent with a 
presumptively positive result for cocaine base.  Of these eight, only one (quinine) 
dissolved during the second step while the solvent remained pink, a further 
presumptive positive result for cocaine base.  The other seven compounds either did 
not dissolve while the solution remained pink, or did not dissolve while the solution 
changed to a purple color.  Both results are inconsistent with a presumptive positive 
as the persistent presence of blue flecks in step 2 is indicative of a negative or 
inconclusive result (6).  Phenobarbital, as mentioned previously, was tested at a 
much lower concentration than the other adulterants.  This adulterant, when tested, 
turned blue briefly, then dissolved during the first step and the reagent solution 
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remained pink.  This result is inconclusive as it may have reacted differently if tested 
in the same manner as the other adulterants.  Table 8 shows the results of the 
individual tests while Table 9 shows the results of the mixtures.  The information 
presented in these tables is organized so that step 1 indicates the color of the sample 
powder observed after 2 minutes with a (—) indicating that the sample powder had 
dissolved and was no longer visible. Step 2 indicates the color of the reagent solution 
2 minutes after the addition of hydrochloric acid to the cobalt (II) 
thiocyante/glycerin/acetic acid solution. Step 3 indicates the color of the aqueous 
and organic layers. The notation ―Pink/Clear‖ indicates the top, or aqueous, layer 
was pink and the bottom, organic, layer was clear. 
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Table 8:  Summary of Scott test results for single adulterant samples.  
 
 Adulterant Step 1 Step 2 Step 3 
Acetaminophen — Pink Pink/Clear 
Acetylsalicylic Acid White Pink1 Pink/Clear 
Atropine — Pink Pink/Clear 
Benzocaine — Pink Pink/Clear 
Caffeine — Purple Pink/Clear 
Creatine Monohydrate — Purple Pink/Clear 
Creatinine — Pink Pink/Clear 
Diltiazem Blue Purple2 Pink/Clear 
Diphenhydramine Blue Purple Pink/Clear 
Hydroxyzine 2HCl Blue Pink Pink/Clear 
Inositol — Purple Pink/Clear 
Levamisole Blue Pink2 Pink/Clear 
Lidocaine Blue Pink2 Pink/Clear 
Mannitol —3 Purple Pink/Clear 
Phenacetin Blue3 Purple Pink/clear 
Phenobarbital* — Pink Pink/Clear 
Piracetam —3 Purple Pink/Clear 
Prilocaine HCl — Pink Pink/Clear 
Procaine White Purple Pink/Clear 
Quinine Blue4 Pink Pink/Clear 
Tetramisole Blue Pink2 Pink/Clear 
Thiamine HCl —3 Pink Pink/Clear 
Xylazine HCl — Purple Pink/Clear 
 
1:  Flecks of white powder still visible in liquid 
2:  Flecks of blue powder still visible in liquid 
3:  Reagent liquid darkened slightly upon contact with sample, appeared purple-pink 
4:  Powder did not turn blue instantly but did so slowly over one minute.  
*Results regarding phenobarbital are inconclusive due to the lower concentration it 
was tested at.  Sample turned blue briefly then dissolved during the first step.  It 
cannot be concluded that it would react the same way if tested in a higher 
concentration.  
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Table 9:  Summary of Scott test results for adulterant mixtures.   
(A = Acetaminophen, B = Acetylsalicylic Acid, C = Atropine, D = Benzocaine, E = 
Caffeine, F = Creatine Monohydrate, G = Creatinine, H = Diltiazem, I = 
Diphenhydramine, J = Hydroxyzine, K = Inositol, L = Levamisole, M = Lidocaine, 
N = Mannitol, O = Phenacetin, Q = Piracetam, R = Prilocaine, S = Procaine, T = 
Quinine, U = Tetramisole, V = Thiamine, W = Xylazine) 
 
Mixture Components Step 1 Step 2 Step 3 
3.01 AHT Blue Purple Pink/Clear 
3.02 BIU Blue Purple1 Pink/Clear 
3.03 BLM Blue Pink1 Pink/Clear 
3.04 DES — Purple Pink/Clear 
3.05 FKN — Purple Pink/Clear 
3.06 FLN Blue Purple1 Pink/Clear 
3.07 HJM Blue Purple Pink/Clear 
3.08 IJM Blue Purple Pink/Clear 
3.09 ILM Blue Purple1 Pink/Clear 
3.10 LMR Blue Pink1 Pink/Clear 
5.1 ABLQW — Purple Pink/Clear 
5.2 BIJMU Blue Pink1 Pink/Clear 
5.3 DFKTV — Pink Pink/Clear 
5.4 EGNOS — Purple Pink/Clear 
5.5 HJLMR Blue Pink1 Pink/Clear 
5.6 CDRTV — Pink Pink/Clear 
8.1 AHT & EGNOS — Purple Pink/Clear 
8.2 BLM & CDRTV Blue Pink1 Pink/Clear 
8.3 DES & BIJMU Blue Pink1 Pink/Clear 
8.4 BIU & HJLMR Blue Purple1 Pink/Clear 
8.5 FKN & ABLQW — Pink Pink/Clear 
8.6 HJM & DFKTV Blue Purple1 Pink/Clear 
10.1 HJLMR & EGNOS Blue Purple Pink/Clear 
10.2 BIJMU & EGNOS Blue Purple1 Pink/Clear 
10.3 BIJMU & CDRTV Blue Purple Pink/Clear 
10.4 CDRTV & EGNOS Blue Purple Pink/Clear 
10.5 ABLQW & CDRTV Blue Purple Pink/Clear 
10.6 ABLQW & DFKTV — Pink Pink/Clear 
 
1:  Flecks of blue powder still visible in liquid 
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4.  DISCUSSION 
4.1 Analysis of Drug Purity Data between the Years of 2001 and 2011 
According to information obtained from the National Forensic Laboratory 
Information System (NFLIS) annual reports between the years of 2001 and 2011, 
street drug purity fluctuates significantly from year to year (12–22).  These reports 
show that heroin purity has decreased over the last 11 years while cocaine purity 
appears to fluctuate but is currently in an upward trend.  The average percent purity 
information presented in these reports is reflected in Figures 6 and 7.  These graphs 
were created by reviewing the drug purity information in the NFLIS annual report 
for each year between 2001 and 2011. Certain laboratories are missing data points 
over the years because not every report listed data from the same laboratories from 
one year to the next.  In addition, the protocols for quantitative analysis to determine 
percent purity are different between each lab.  The Massachusetts (MA) State Police 
Crime lab routinely tests for purity of heroin and cocaine samples, the Texas 
Department of Public Safety conducts analysis only on powder samples of 200 grams 
(g) or more, Baltimore City Police Department conducts purity analysis on samples 
greater than or equal to 7 g, while the Austin police department conducts purity 
analysis on all samples including residue.  Whether street drug purity is increasing or 
decreasing, it is important to obtain a better understanding of what is present in these 
samples in addition to the drugs of abuse.   
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Figure 6:  Heroin purity from 2001 to 2011 as reported by four forensic 
laboratories in the NFLIS annual reports.  
 
 
Figure 7:  Cocaine purity from 2001 to 2011 as reported by four forensic 
laboratories in the NFLIS annual reports.  
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4.2 Forensic Pathology Considerations in the Incidence of Drug Adulterant 
Exposure 
The adulterants present in seized drug samples are sometimes dangerous 
enough to be considered public health issues.  Presented below is an exploration of 
the side effects resulting from exposure to several common drug adulterants. The 
investigation into each adulterant was approached as follows: First, thorough 
research into the scientific literature was conducted in order to elucidate what is 
understood about the structure and pharmacodynamics of each adulterant. Next, a 
question was asked regarding how the effects of the drug may impact the body. The 
literature was then explored once again to determine if these effects are, in fact, 
observed.  Finally, the information was collected and compiled then presented as a 
synopsis to assist forensic pathologists in conducting their investigation.  The drug 
adulterants investigated here are levamisole, atropine, phenacetin, and the topical 
anesthetics: lidocaine, prilocaine, benzocaine, and procaine.  These adulterants were 
chosen for the following reasons: levamisole was chosen because of the known 
immunomodulating effects of this drug and the large number of case reports 
regarding this drug and the devastating side effects it has, phenacetin was chosen 
because of the known side effects discussed in the literature and the carcinogenic 
properties it has, atropine was chosen because of the sympathomimetic property it 
shares with cocaine, and the topical anesthetics were chosen because each of the four 
mentioned have been associated with the development of methemoglobinemia. 
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4.2.1 History and Pharmacology of Levamisole 
 Levamisole was originally produced and used as a highly effective 
antihelminth/antiparasitic drug for humans in 1966 (23).  In the years following its 
introduction, it was found that levamisole has an immunomodulating effect on the 
human body (23).  This was first reported by Renoux and Renoux in 1972 who 
reported that levamisole had potentiated the effect of a vaccine to Brucella abortus 
(23,24).  For this reason, interest in levamisole increased and several clinical trials 
were begun to determine its potential for use in patients with immunological 
conditions such as rheumatoid arthritis and immunodeficiency disorders (23,24).  It 
was soon discovered that one major side effect of chronic levamisole exposure was 
agranulocytosis; a condition previously unrecognized as a side effect as it typically 
does not occur in single or acute dosages (25).  As a result, its popularity diminished 
in the research community for several years. Interest reemerged in the late 1980’s and 
early 1990’s as studies were published which reported its potential for use in the 
treatment of melanoma and colon and rectal cancers (26). However, the side effect of 
aggranulocytosis was persistent, and too severe for the drug to be continued in 
widespread use. It was therefore taken off the market for human use in 1999 (27). It 
is still in use today in veterinary medicine as an antihelminth/antiparasitic treatment 
for farm animals (23). Levamisole has since reemerged as a cocaine adulterant with 
instances reported as early as 2003 (28). Since then, the numbers of cases of 
levamisole-related complications with associated drug abuse that has been reported is 
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enumerable. Scientific publications related to levamisole have also begun to increase 
once again. 
Figure 8 shows data acquired using SciFinder® software which displays the 
abundance of levamisole-related scientific articles published from the year 1967 to 
2013. The graph shows the rise and fall of interest in levamisole in the scientific 
community. When looking at the graph, one can see the increase in interest shortly 
after its emergence on the market with the peak of its popularity being in 1979. This 
was likely due to the discovery of its immunomodulatory effects and the number of 
clinical trials that had arisen as a result. The recognition of the negative side effects is 
reflected in the decline observed from 1979 onward until a short-lived, slight increase 
in interest in the mid-1990s. The studies continued until it was officially taken off of 
the market in 1999. The graph shows that this year had the lowest number of 
levamisole related articles since the height of its popularity in the mid-1970s. In the 
early 2000s, this drug re-emerged as a cocaine adulterant and interest was once again 
increased. Since the year 2000, levamisole-related articles have begun to increase 
steadily once again. 
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Figure 8: Levamisole related articles published in the literature by year. Data 
acquired using SciFinder® software by searching for the keyword ―Levamisole‖ and 
using the integrated software to organize the results as displayed. 
 
The mechanism of action of levamisole has been elucidated in the past and it 
has been determined that levamisole stimulates antibody production in B and T 
lymphocytes, and increases immune function in monocytes, and macrophages (29). 
This stimulating functionality is what prompted the interest in using levamisole to 
modulate immune function in various clinical trials in the past. However, it is exactly 
this stimulating function, which causes the primary pathogenesis of levamisole.  Here 
the question is posed: if levamisole stimulates the function of the immune system and 
antibody proliferation, could the pathological side-effects be the result of the 
production of a self-reactive antibody?  An immune system stimulated by levamisole 
may lack specificity and it is therefore more likely that a self-reactive antibody will be 
produced. 
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Through a review of the literature, it has been concluded that this is, in fact, 
the case. The primary pathology of levamisole is a specific type of agranulocytosis 
known as neutropenia (25). This is characterized by a number of circulating 
neutrophils less than 400 cells/cubic millimeter (mm3).  The cause of this condition 
has been determined to be that levamisole induces the production of anti-neutrophil 
antibodies (25,30). These anti-neutrophil antibodies cause an autoimmune response 
leading to the destruction of circulating neutrophils (25).  The exact manner at which 
levamisole stimulates the production of these antibodies is unclear (31).  However, 
an association between levamisole-induced agranulocytosis and the human leukocyte 
antigen (HLA) B27 genotype has been reported (23,25).  The HLA genetic loci codes 
for the major histocompatibility complex proteins.  These are cell-surface proteins 
which the immune system uses to differentiate between self and nonself cells. If 
levamisole altered the expression of this gene, it could cause an autoimmune 
response to occur.  The connection and mechanism of action between levamisole 
and this genotype has not been confirmed and more investigation in this area is 
necessary. 
This autoimmune response has another effect which leads to the development 
of a characteristic purpuric rash (27).  The purpura observed in patients with this 
condition typically begins in the more distal portions of the body such as the tip of 
the nose and ears, but can progress inward and affect additional areas of the body if 
left untreated (32).  The purpura is the presentation of necrotizing vasculitis.  The 
induction of the antineutrophil antibodies leads to the formation of antibody-antigen-
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antibody complexes within the bloodstream.  These complexes eventually become 
large enough to occlude blood flow through vascular tissue resulting in thrombosis, 
vasculitis, and subsequently the death and necrosis of the surrounding tissue leading 
to the purpura observed (25,31,33).  This phenomenon is known as leukocyte 
agglutination and is common when blood cells are targeted by an antibody.  As an 
example, this also occurs when the wrong blood type is given during a transfusion, 
though on a much larger scale than this case. 
4.2.1.1 Forensic Pathology Considerations for Levamisole 
 Based on what is known about the pathology of chronic levamisole exposure, 
there are several signs and symptoms that a forensic pathologist could look for to 
determine if a decedent has been exposed to levamisole. Levamisole toxicity has not 
been shown to occur as a result of a single dose or overdose, but rather, consistent 
exposure over time (23).  However, this is unfortunate as individuals who regularly 
use cocaine, as the result of addiction or otherwise, have the potential to be exposed 
to levamisole regularly for extended periods of time; particularly if they purchase 
cocaine from the same dealer. The initial development of agranulocytosis will cause 
a significant decrease in the capabilities of the individual’s immune system. A 
pathologist may notice a trend of infections when looking through the decedent’s 
medical history; particularly with oropharngyeal complaints or soft tissue infections 
(31).  Their weakened immune system also puts them at greater risk for acquired 
infections such as hepatitis C or methicillin-resistant Staphylococcus aureus (32). In 
addition, the characteristic purpura observed on the distal portions of the body can 
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be a significant telltale sign of chronic levamisole exposure. Also, the induction of 
the proliferation of antineutrophil antibodies allows for a blood test to detect the 
presence of these antibodies.  While it will not be confirmatory, this test can be used 
to at least suggest the potential involvement of levamisole.  
The half-life of levamisole has been found to be less than that of cocaine (31).  
This means that levamisole will likely not be detected in the decedent’s blood stream. 
However, it has been shown that levamisole can be detected in an individual’s urine 
(34).  The symptoms described in conjunction with a positive drug screen for cocaine 
should give the pathologist a high degree of suspicion for the incidence of levamisole 
exposure.  
 In addition to the forensic pathologist, emergency room physicians may 
benefit from learning of the signs and symptoms of levamisole poisoning.  If an 
individual presents to the emergency room (ER) with the previously mentioned 
complaints and a history of drug abuse is admitted or suspected, it might be worth 
testing for agranulocytosis. 
In July 2009, the Drug Enforcement Administration (DEA) reported that 
approximately 69% of seized cocaine samples contained levamisole as an adulterant 
(35). This was a significant increase from the previous year when the number was 
estimated at 30% (27). Since then, no more recent information regarding the 
percentage of cocaine contaminated with levamisole has been released from the 
DEA, however, case reports of symptoms and ailments from levamisole with 
associated cocaine use have continued to be reported. 
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4.2.2 Pharmacology of Atropine 
 Atropine is the prototypical muscarinic antagonist drug (29). This drug 
functions by altering the parasympathetic tone in the body (29).  The central nervous 
system (CNS) has two major divisions, these being the sympathetic and 
parasympathetic systems (36). The sympathetic nervous system is also known as the 
―fight or flight‖ system. It is responsible for the body’s physiological response to 
stress. When the sympathetic nervous system is excited, the pupils dilate, heart rate 
and blood pressure are increased, blood flow to the muscles is increased, 
gastrointestinal motility is decreased, and excretions such as saliva and sweat are 
decreased, among other things (36). These responses prepare the body for a fight or 
flight response.  The parasympathetic system is also known as the ―rest and digest‖ 
system and causes the opposite reactions to occur. When the parasympathetic 
nervous system is excited, the pupils constrict, heart rate and blood pressure 
decrease, gastrointestinal motility is increased, etc. (36). Both systems are acting on 
the body at all times causing a mediated response from all organs affected.  When 
circumstances arise causing an increase in activity from one system or the other, the 
influence, or tone, of that system is increased.  The parasympathetic nervous system 
uses two primary receptors to augment the parasympathetic tone affecting the body: 
the nicotinic and muscarinic receptors (36). The nicotinic and muscarinic receptors 
located in the peripheral nervous system are responsible for initiating a 
parasympathetic response in the various organs affected.  The primary 
neurotransmitter used by the parasympathetic nervous system to initiate a signal 
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from these receptors is acetylcholine (36).  Atropine functions by blocking the 
binding capabilities of acetylcholine at muscarinic receptors in parasympathetic 
ganglia (29). This causes the parasympathetic tone to decrease throughout the body. 
As a result, the sympathetic tone increases, causing an increase in fight or flight 
activity. 
 Atropine is used therapeutically to elicit a sympathetic response in the body, 
or to counteract the responses observed from the parasympathetic nervous system 
(29).  It is used by optometrists and ophthalmologists to dilate the pupils for 
procedures, and is sometimes administered to increase heart rate and counteract 
bradycardia during a myocardial infarction (29).  As a drug adulterant, it is likely 
used due to the stimulating effects observed as a result of a heightened sympathetic 
tone. Cocaine, as an example, is a sympathomimetic drug, meaning it mimics the 
effects of the sympathetic nervous system (37).  The coupling of the anticholinergic 
effects of atropine with the sympathomimetic effects of cocaine cause a more 
intensely stimulating ―high‖ for the user of the adulterated cocaine product. 
4.2.2.1 Forensic Pathology Considerations for Atropine 
 One potential risk of anticholinergic drugs is the potential for overdose 
resulting in anticholinergic toxicity. This is a syndrome that can be fatal if untreated. 
It is characterized by symptoms resembling the over-activity of the sympathetic 
nervous system. The individual may present hypertension, hyperthermia, 
tachycardia, extreme mydriasis, dry and flushed skin, tremors and ataxia, seizures, 
disorientation and delirium, and/or coma (38). 
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Since both atropine and cocaine function to stimulate the influence of the 
sympathetic nervous system, the question was asked: what are the similarities and 
differences between an overdose of atropine and an overdose of cocaine?  After 
reviewing the literature, it was revealed that this is indeed the case.  The symptoms 
of anticholinergic toxicity are very similar to the symptoms of sympathomimetic 
toxidrome produced by cocaine overdose (37–39).  They are so similar that they 
could be difficult to distinguish by physical observation during an autopsy. However, 
there are a few key symptoms that can be used to determine the difference during a 
careful physical examination. In sympathomimetic toxidrome brought on by cocaine 
overdose, the pupil dilation observed is reactive to light while in cases of 
anticholinergic toxicity, it is not (39). Also, sympathomimetic syndrome presents 
diaphoresis, or profuse perspiration, while anticholinergic toxicity causes a notably 
dry and flushed skin. Additionally, sympathomimetic substances increase bowel 
motility and urination leading to more intense bowel sounds while anticholinergic 
toxicity decreases gastrointestinal motility and causes urinary retention.  Figure 9 
summarizes the similarities and differences seen between sympathomimetic 
syndrome and anticholinergic toxicity. 
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Figure 9: Venn diagram illustrating the similarities and key differences between 
sympathomimetic toxidrome (cocaine overdose) and anticholinergic toxicity 
(atropine overdose). 
 
A thorough physical examination focusing on these three symptoms should 
allow an emergency room doctor to distinguish between anticholinergic toxicity and 
sympathomimetic syndrome. This will allow the physician to more accurately 
diagnose the patient and provide better care. Additionally, a pathologist may focus 
on the factors outlined in Figure 9 when reviewing the medical history of a deceased 
patient as the cause of death may be attributed to an overdose of atropine rather than 
cocaine. A toxicology screen may be requested to test for the presence and 
concentration of atropine in the decedent. This may explain the findings of a lower 
concentration of cocaine with what appears to be a cocaine overdose. 
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4.2.3 History and Pharmacology of Phenacetin 
 Phenacetin’s use in medicine began in 1887 when it was used as a popular 
analgesic and antipyretic medication (40).  In 1983, it was removed from the United 
States (US) market due to the toxic effects associated with regular use (41).  
Phenacetin has been reportedly found as an adulterant in heroin and cocaine samples 
in the past (42).  It is likely that this is due to the analgesic properties and similar 
appearance to these drugs of abuse.  Additionally, prior to its removal from the 
market, some patients described positive mood-altering effects from phenacetin, 
suggesting that it may also be used in an attempt to modify or enhance the ―high‖ 
associated with the drug product being sold (43).  
Phenacetin is structurally very similar to acetaminophen, and as such it 
functions similarly to provide pain relief. These medications relieve pain by either 
inhibiting the function or formation of enzymes involved in an inflammatory 
response (dilation of blood vessels, sensitization of nerve endings, and increased 
body temperature) (43,44). Acetaminophen is known to be highly hepatotoxic and 
can cause significant damage to the liver if consumed in high doses, while phenacetin 
causes significant damage to the kidneys and bladder.  Here, the question was asked: 
are there structural similarities between acetaminophen and phenacetin that 
contribute to the toxicity observed?  Both compounds contain an amide functional 
group.  These functional groups have the potential to undergo a variety of chemical 
reactions, typically through a nucleophilic attack of the carbonyl carbon (45).  When 
highly reactive compounds are present in the body, they have the potential to react 
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with cellular proteins and other components; this can lead to the destruction of 
tissues and contribute to the toxic effects of these compounds. 
4.2.3.1 Forensic Pathology Considerations for Phenacetin 
 Phenacetin has been found to cause renal papillary necrosis and tumor 
generation in the bladder and kidneys.  These effects were observed in patients 
throughout the early to mid-1900’s who habitually consumed analgesic medicine 
(40). It wasn’t long until phenacetin was determined to be the causative agent in 
these medications resulting in its removal from the market. 
 Upon review of the literature performed in this research, it was determined 
that the damage is caused, not by phenacetin itself, but rather by the formation of 
reactive metabolites. There are several metabolic pathways which phenacetin 
undergoes during elimination, two of which will be discussed here; namely, the O-
dealkylation pathway and the N-hydroxylation pathway.  
The O-dealkylation pathway removes the C2H5 group from the aromatic 
oxygen resulting in the formation of acetaminophen (see Figure 10 for chemical 
structure of Phenacetin) (41).  After this step, the molecule is further metabolized as 
acetaminophen would be.  The metabolism of acetaminophen produces the 
intermediate N-acetyl-p-benzoquinone imine (NAPQI) which is the compound 
responsible for the hepatotoxicity (41).  NAPQI is highly electrophilic and is capable 
of covalently binding with proteins and other structural components of hepatic cells 
resulting in the destruction and necrosis of the liver (41). However glutathione 
(GSH), a powerful endogenous antioxidant in the liver, is responsible for 
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neutralizing such reactive molecules thus protecting hepatic cells from oxidative 
metabolites (41).  It is not until the amount of NAPQI produced overwhelms the 
GSH in the liver that the hepatotoxic effects are observed. Since the O-dealkylation 
pathway is only one metabolic route of phenacetin, it is not likely that enough 
NAPQI could be produced to deplete the GSH present in the liver.  
 
Figure 10: Chemical structures for acetaminophen and its toxic metabolite 
(NAPQI) (left) and phenacetin and its toxic metabolite O-Et-NAPQI (right). 
 
The N-hydroxylation pathway results in the formation of a compound 
structurally similar to NAPQI known as O-ethyl-N-acetyl-p-benzoquinone imine (O-
Et-NAPQI) (41). This product is formed in the bladder as opposed to the liver like 
NAPQI. This is because it is a result of the hydrolysis of glucuronide and sulfonyl 
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conjugate metabolic products (which are less stable than the analogs produced by 
acetaminophen metabolism) in the acidic environment of the bladder (41).  The 
conjugates are hydrolyzed to N-OH-phenacetin, which is oxidized to O-Et-NAPQI 
(41). O-Et-NAPQI is a highly unstable and reactive electrophile. This compound, 
like NAPQI, reacts with structural proteins of tissue cells causing apoptosis and 
necrosis. However, O-Et-NAPQI is electrophilic enough to also bind to 
deoxyribonucleic acid (DNA) nucleotides, resulting in mutagenesis and subsequent 
tumor generation (41). Based on information gathered from the literature, it can be 
concluded that it is the production of toxic metabolites from these compounds that is 
responsible for their toxicity rather than the presence of the reactive amide functional 
group. 
 Acetaminophen and phenacetin toxicity can be distinguished by their location 
of action in the body. Acetaminophen primarily affects the liver while phenacetin 
primarily affects the bladder and kidneys. The pathologist can use both gross and 
histological techniques to check for signs of the toxic effects in these organs.  Medical 
histories may show complaints of painful urination with an elevated number of 
leukocytes present in the urine (46).  The initial symptoms closely resemble that of a 
urinary tract infection and a misdiagnosis of this may be present in their medical 
histories as well (46). 
4.2.4 Use and Pathology of Topical Anesthetics 
 Topical anesthetics are among the most common types of drug adulterants 
used to cut cocaine and heroin. They are frequently used as an adulterant in cocaine 
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because they mimic the anesthetic effect cocaine has on the lips and gums. It is 
common for buyers to test the quality of cocaine they intend to purchase by putting a 
small amount on their finger and rubbing it around their mouth (34).  If their mouth 
goes numb, they think they have a high purity sample. Drug dealers and 
manufacturers will sometimes add various topical anesthetics to their products in 
order to mimic the effects of the cocaine. The buyer’s mouth will go numb, but it will 
be a result of the adulterant rather than just the cocaine. In heroin it is believed to be 
added in order to ease the pain of injection for intravenous drug users by locally 
numbing the injection site. 
 Topical anesthetics are widely used in medicine for a myriad of different 
procedures and purposes.  They typically function by increasing the threshold for 
excitability (usually by blocking sodium channels on the neuron, increasing the 
threshold to trigger an action potential) thereby reducing conductivity of nerve 
endings and subsequently reducing sensation (29).  Additionally, some topical 
anesthetics such as prilocaine and lidocaine, are used in cardiovascular medicine to 
counter various cardiac arrhythmias by performing the same sodium channel 
blocking function on cardiac pacemaker cells (29). This being the case, the question 
was asked: is the pathology of these compounds related to the potential cardiac 
complications resulting from their influence on sodium channels?  However, it has 
been found in the past that many topical anesthetics can cause the potentially fatal 
condition, methemoglobinemia. Methemoglobinemia is a condition in which the 
concentration of methemoglobin in the blood exceeds the normal levels.  Typical 
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levels of methemoglobin in the blood are between 1-3% while symptoms of 
methemoglobinemia typically manifest around levels of 10-20% (47).  
Methemoglobin is formed when the iron atom present on the hemoglobin molecule 
is oxidized from the ferrous state (Fe2+) to the ferric state (Fe3+) (48).  Iron in this 
state binds much more strongly to oxygen.  Because of this, oxygen cannot be 
surrendered to the tissues and as a result, the tissues will be deprived of oxygen.  The 
four topical anesthetics investigated here (benzocaine, lidocaine, prilocaine, and 
procaine) have each been associated with the development of methemoglobinemia. 
 It has been found that lidocaine and prilocaine are metabolized to oxidative 
compounds, namely 2,6-xylidine and O-toluidine respectively (Figure 11) (49).  It is 
these metabolites which are primarily responsible for the oxidation of the ferrous iron 
leading to methemoglobin development associated with prilocaine and lidocaine use 
(49).  O-toluidine has a higher potential to cause this oxidation to occur; this is 
reflected in the literature reports and medical practices associated with these topical 
anesthetics.  In fact, prilocaine has lost popularity in its use as a cardiovascular drug 
and is now used tentatively in dental procedures due to the high rate of incidence of 
methemoglobinemia (29). 
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Figure 11: Lidocaine and its oxidative metabolite, 2,6-xylidine (left) and 
prilocaine and its oxidative metabolite, O-toluidine (right). 
 
 In 2012, the Food and Drug Administration (FDA) released a 
communication to warn of the dangers of methemoglobinemia from benzocaine use 
(50). In this document, it was mentioned that there have been 319 cases of 
methemoglobinemia associated with the use of benzocaine sprays and gels reported 
to the FDA’s Adverse Event Reporting System database (a cumulative database 
which collects reports submitted by healthcare professionals). The 319 cases included 
seven deaths, thirty-two life-threatening cases, and 216 cases described as serious. 
Interestingly, upon review of the cases, the development of methemoglobinemia 
from topical sprays or gels was found not to be dose dependent. It was found to 
develop after a single spray as well as when administered in excessive amounts (50). 
The FDA has published several documents and bulletins to warn consumers about 
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the potential for the development of this condition from the use of benzocaine 
containing products (51). 
Of the four topical anesthetics investigated in this report, procaine has been 
found to have the least potential for the development of methemoglobinemia. While 
the mechanism for the development of methemoglobinemia from benzocaine use 
was not found as it was for prilocaine and lidocaine, and thus could not be conveyed 
here, the potential for this condition to arise following the consumption of cocaine or 
heroin adulterated with benzocaine is high. 
4.2.4.1 Forensic Pathology Considerations of Topical Anesthetics 
 The onset of methemoglobinemia can occur quickly and may result in an 
emergency room presentation with cyanosis unresponsive to oxygen administration 
(47).  Medical histories may describe the signs and symptoms of methemoglobinemia 
including lethargy, syncope, pale grey skin, respiratory depression, and mucous 
membranes and nail beds appearing cyanotic. Diagnosis of methemoglobinemia is 
based on the cyanosis being unresponsive to oxygen administration and arterial 
blood which appears ―chocolate brown‖ (52).  The chocolate brown appearance of 
the blood is the largest indication of methemoglobinemia and one of the symptoms 
which distinguishes it from similar conditions such as carbon monoxide poisoning. 
In the instance of carbon monoxide poisoning the blood appears bright red. 
 Methemoglobinemia causes the body’s tissues to become starved of oxygen 
which can result in serious complications including coma and death. These dangers 
can be exacerbated when experienced in conjunction with depressants such as 
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alcohol and heroin which themselves cause respiratory depression. Local anesthetics 
present in street drugs can subject unknowing individuals to a greater risk of fatal 
respiratory depression or oxygen starvation of the brain.  
4.3 Chemical Analysis of Colorimetric Spot Tests 
While a significant amount of information is available regarding spot test 
cross-reactivity with single component samples, very little investigation has been 
done into how mixtures of components may affect the outcome.  In this experiment, 
it was observed that some adulterant mixtures have an effect on the results of 
colorimetric spot tests in unexpected ways.  The results become increasingly complex 
when more components are present in a sample.  While the results observed herein 
were not consistent with the expected results for presumptively positive identification 
of the drugs these tests are commonly used for, it can be concluded that the presence 
of adulterants has the potential to affect the results of a colorimetric spot test enough 
to lead to a ―false negative‖ conclusion.  Based on constantly fluctuating trends of 
street drug purity, this is an ongoing, relevant issue in forensic drug analysis.  
4.3.1 Marquis Reagent Mechanism and Reactivity with Aromatic Rings 
 While none of the twenty-three adulterants or the twenty-eight mixtures 
tested were shown to react with the Marquis reagent in a manner that could be 
considered a ―false positive‖ for any of the illicit substances it is commonly used for, 
there was a significant amount of information gained by observing the way this 
reagent reacts with adulterants and mixtures of increasing complexity.  The final 
color of some mixtures was observed to be a combination of the colors seen for each 
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component individually.  However, it was also observed that the presence of 
additional compounds, either reactive or non-reactive, impacted the color 
development beyond this outcome of mixing two or more colors to create a new one.  
 The reaction mechanism for the Marquis reagent has been elucidated and 
described previously in the literature (4).  This reaction is an electrophilic aromatic 
substitution resulting in a condensation reaction with a dimeric product (8,45).  The 
sulfuric acid and formaldehyde reagent solution reacts with the aromatic ring moiety 
on morphine, heroin, MDMA, amphetamine, and methamphetamine to condense 
two molecules of the compound into one dimeric complex (see Figure 12) (4). In this 
reaction, the formaldehyde is protonated in the acidic solution making the carbonyl 
carbon electrophilic.  This results in a nucleophilic attack from the electrons of the 
aromatic ring causing a substitution reaction.  The oxygen then leaves as water 
leaving behind an electrophilic carbocation which reacts with the aromatic ring of a 
second drug molecule to form a dimer.  Once the dimer is formed it is oxidized in the 
acidic solution resulting in the formation of a color producing carbocation (4). 
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Figure 12: Marquis reagent mechanism.  
 
When looking at the structure of the molecules which exhibited a color 
change reaction with the Marquis reagent during testing, one can see that each 
compound contains at least one aromatic ring (Figure 13).  It is likely that the 
Marquis reagent reacted in a similar manner to the reaction seen in Figure 12.  The 
condensation of these compounds resulted in the production of similar colored 
dimers. 
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Figure 13:  Chemical structures of adulterants which resulted in a color change 
when tested with the Marquis reagent.  
 
When looking at the mixture results discussed previously, some observations 
made were somewhat predictable.  When these compounds were mixed, the 
resulting color could only be described as a mixture of the colors observed when 
reacted individually. Some examples of these tests are mixtures 3.07 and 3.10. 
Mixture 3.07 contained diltiazem, which did not react individually, hydroxyzine, 
which reacted to cause a yellow color development, and lidocaine, which reacted to 
cause a pink-red color development. When the mixture was tested, the resulting color 
could best be described as orange. This is somewhat expected as the mixture of 
yellow and red would create orange. Mixture 3.10 contained levamisole, which 
reacted to turn the liquid brown, and lidocaine and prilocaine which both reacted to 
create a pink-red color. The final color of the mixture could best be described as 
reddish orange-brown. This is likely due to each molecule reacting with the reagent 
resulting in the development of the colored products observed when tested 
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individually.  The colors mix in solution and are observed as the color combination 
created. 
Similarly, as the mixtures became more and more complex, the final colors 
began to be observed as various shades of brown. The five, eight, and ten-component 
mixtures (not including those containing diphenhydramine for reasons discussed 
below) all had final colors that could best be described as different shades of brown. 
This is likely due to the mixtures of the various, yellow, red, brown, and green colors 
caused by each compound mixing in solution to form brown. 
The diphenhydramine reaction was particularly interesting.  This compound 
reacted immediately and intensely with the Marquis reagent.  The liquid turned a 
bright yellow-green upon contact with the sample and proceeded in a unique manner 
by forming solid aggregates of material, and turning the liquid a very dark red-black.  
In addition, diphenhydramine reacted very differently when in combination with 
other compounds.  When looking at the structure of diphenhydramine (Figure 13) it 
can be seen that this compound contains not one but two aromatic rings.  Based on 
what is known about the mechanism of the Marquis reaction, it would be expected 
for the diphenhydramine molecule to react intensely as it is possible that this reaction 
is occurring twice on the same molecule.  While hydroxyzine also has two aromatic 
rings, the presence of the chlorine atom likely hinders the occurrence of this reaction 
on that aromatic ring moiety.  Chlorine’s electronegative properties alter the 
electrostatic environment of the aromatic ring resulting in the preferential reactivity 
of the other aromatic ring moiety of the molecule. 
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It is likely that the solid, insoluble material is a direct result of the 
condensation caused by the Marquis reagent.  Since the diphenhydramine molecule 
has two identical aromatic rings, it essentially has two locations where the 
condensation reaction can occur.  It is likely that one diphenhydramine molecule can 
be condensed twice to form a trimer.  Each trimer would then also have two active 
sites where another diphenhydramine molecule could be condensed and so on and so 
forth.  The solid material observed during the reaction is likely the result of this 
condensation reaction recurring until the complex becomes so large that it becomes 
insoluble.  This is further supported by the absence of these solid aggregates in 
mixtures containing diphenhydramine with additional, reactive components.  The 
other molecules likely served as competitive reactants and inhibited the formation of 
aggregates large enough to precipitate out of solution.  This could have been caused 
by the condensation of diphenhydramine with any combination of other adulterants 
present in the mixture as well.  The unstable carbocation has the potential to react 
with any nucleophile present in the solution (8,45). 
The consistent condensation of diphenhydramine molecules is further 
supported by the change in color over time from yellow-green to red.  This change in 
color is likely caused by a phenomenon known as bathochromic shift.  As colored 
aromatic systems extend in length, there is an observed shift in the absorption and 
transmission of visible light (53).  As the system becomes longer, there is a shift from 
the transmission of lower wavelengths to higher wavelengths (53). This corresponds 
to the color change observed during this reaction as the initial color observed is a 
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yellow-green (lower wavelength) and, as the reaction progresses a red (higher 
wavelength) aggregate is formed. 
It should be noted that there is some similarity in the orange and red-orange 
colors observed in mixtures containing diphenhydramine and the orange colors 
observed among positive reactions with amphetamine/methamphetamine, MDMA, 
and heroin/morphine.  While the target compounds do initially display an orange 
color development, a presumptively positive result is based on the change from the 
initial orange color to either a brown, black, or purple color.  This color change 
occurs over 2-3 minutes, or in the case of amphetamine/methamphetamine, within 
12 seconds.  The final color after this time period is the one used to inform the next 
step of sample analysis.  The mixtures containing diphenhydramine differed in that 
the initial color, which occurred within seconds of exposure, was a bright yellow-
green.  The yellow-green color changed to the orange or red-orange colors shown in 
Figure 5 over two minutes.  In other words, the final color of the mixtures containing 
diphenhydramine appeared similar to the initial color of a presumptively positive 
result for the targeted drugs of abuse.  Therefore, the observations made during 
testing were inconsistent with what would be expected for a positive result.  This 
further enforces the necessity for proper understanding and careful observation by the 
analyst with presumptive testing using spot tests.   
Diphenhydramine is of particular interest as it has a high potential for use as 
an adulterant in heroin due to its well-known sedative properties.  Based on the 
information obtained in this experiment, it would be interesting to explore how 
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diphenhydramine may affect the outcome of a spot test when tested in combination 
with heroin, morphine, amphetamine, methamphetamine, or MDMA. 
Hypothetically, the rapid and vibrant yellow-green color observed initially in the 
diphenhydramine reaction as well as the orange to red-orange color observed in 
mixtures, could mix with the colors produced by the target analytes of this test.  The 
yellow-green or red-orange from diphenhydramine mixed with the final purple color 
of heroin or morphine could mix to a dark brown or black color. This may cause the 
analyst to suspect the presence of amphetamines or MDMA rather than heroin or 
morphine, thus misinforming their analysis. 
In addition to the variations among the mixtures described, some unexpected 
results occurred with mixture 3.01. This mixture consisted of three components 
(acetaminophen, diltiazem, quinine) which did not react with the Marquis reagent 
when tested individually.  However, when mixed in equal parts and tested together, 
they produced a brown color change within two minutes, which darkened over 
fifteen minutes of observation.  It is unclear what may have caused this change in 
reactivity to occur.  This observation prompted further testing into different 
combinations of the components of mixture 3.01.  Two component mixtures AH, 
AT, and HT; acetaminophen/diltiazem, acetaminophen/quinine, and 
diltiazem/quinine respectively, were made using the same mortar and pestle method 
described previously.  These mixtures were tested using the Marquis reagent in the 
same manner as all previous tests (testing was not performed using the modified 
Scott test).  It was observed that mixtures AH and HT exhibited the light brown 
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color change similar to that observed in mixture 3.01 while mixture AT did not 
(results not shown).  However, these color changes were slower to develop than 
observed for 3.01.  The light brown color did not become apparent until 
approximately 5 minutes after exposure to the reagent as opposed to two minutes as 
observed with mixture 3.01.  These results suggest that the difference in reactivity is 
somehow related to diltiazem, however, what effect the presence of this compound 
has on the reaction is unclear.  Based on the mechanism of the Marquis reagent, it is 
possible that the dimeric condensation products formed from two of the same 
compounds, or a complex of acetaminophen and quinine, did not result in a colored 
product, however, a condensation product formed from diltiazem and either 
acetaminophen or quinine did.  This is only a hypothesis and more testing and 
investigation would be required to arrive at this conclusion with any certainty.   
The results from the various mixtures suggest that testing for cross reactivity 
among individual compounds alone may be insufficient for understanding the 
specificity of a given spot test.  It is shown here that the presence of multiple 
adulterants can have an effect on the results observed from the Marquis reagent.  
These reactions can cause a color change where one previously wasn’t observed and 
they can react in such a way as to cause the expected color of one component to 
appear entirely different.  While the mixtures observed here did not result in the 
development of any expected presumptively positive colors, these results 
demonstrate the potential for misinterpretation that mixtures may generate.   
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4.3.2 Modified Scott Test Results and Interpretation 
 The mechanism for the modified Scott test is not fully understood by the 
scientific community to date.  Several sources have suggested that the pink to blue 
color changes are the result of the formation of charged complexes of cobalt (II) 
thiocyanate and the cocaine molecule (54,55).  However, the specifics of this 
mechanism and the geometry of the resulting colored complex are not known 
(8,54,55).  For this reason, confident conclusions regarding the similarities among 
the structures of reactive compounds cannot be made here.  However, there is much 
to be said regarding the results observed among the mixtures of compounds tested in 
this experiment.  
 
Figure 14:  Chemical structures of adulterants which resulted in a blue presence 
during the first step of the Modified Scott Test.  
 
Unlike the Marquis reagent, the modified Scott test results for a given 
adulterant did not appear to be affected by the presence of other adulterants during 
testing.  It cannot be concluded that any one adulterant had an effect on another 
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during any given step of this test without further testing.  For example, if a mixture 
contained one compound which dissolved in the first step and one which turned 
blue, it would appear as though some of the sample would dissolve while the rest 
would remain as blue flecks.  Additionally, if the reagent solution remained pink 
during the second step for one component while another caused a color change to 
purple, the liquid would appear purple regardless of the presence of the non-color 
altering compound.  In other words, it appeared as though each compound present 
in a mixture would react individually with the reagents of this test in order to 
produce the results observed when the compound was tested alone.  This caused the 
results for each mixture to appear as a combination of the individual results for each 
component. 
The appearance of the reagent solution during the second step was closer to 
purple or blue-purple more often when tested with mixtures than with individual 
adulterants.  Likewise, the persistent presence of blue flecks from step 1 to step 2 
increased among mixtures as well.  Again, this is likely the result of components, 
which displayed this result individually reacting among those which did not.  For 
example: during step 1, creatine and mannitol dissolved while levamisole remained 
visible and turned blue.  In step 2 the reagent solution turned purple when tested in 
combination with creatine and mannitol, however remained pink with levamisole 
while blue flecks of powder were still visible.  When the three were tested as a 
mixture (3.06), the liquid remained pink while blue flecks were visible in step 1.  In 
step 2, the liquid turned purple while blue flecks persisted from step 1.  The blue 
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flecks were likely the result of the reaction with levamisole while the purple color in 
step 2 was likely the result of the reaction with creatine and/or mannitol.  This 
supports the conclusion that the presence of additional components did not affect the 
reactions observed, but rather each component reacted in its own, previously 
observed, manner.  
 The complexity of this test has proven to make it highly specific for cocaine.  
While some adulterants and mixtures appeared presumptively positive for cocaine 
base for the first and second step, the test was ultimately negative after the third step 
(Tables 8 & 9).  Every test for both the individual adulterants and the mixtures ended 
with a pink layer over a clear layer, indicating a negative or inconclusive result.  
However, it was observed that the presence of additional components in a sample 
has an effect on the interpretation of the test.  The example described previously 
regarding mixture 3.06 shows how a sample containing cocaine has the potential to 
be considered negative early on.  A positive result has a blue presence in step 1 
(either the liquid or blue flecks in the liquid), and pink liquid with no blue presence in 
step 2.  With mixture 3.06, levamisole turned blue in step 1 and did not dissolve in 
step 2.  Creatine and mannitol dissolved in step 1 and reacted to turn the liquid 
purple in step 2.  It would be interesting to see if these results would be the same had 
the sample contained cocaine base as well.  If so, the sample may be considered 
negative after step 2 since a persisting blue presence and purple liquid are two 
indications of a negative result.  A similar observation was made among many of the 
mixtures tested, particularly when more components were present.  This further 
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reinforces the necessity for analysts to better understand the effects adulterants can 
have on presumptive tests and is a demonstration of the inherent weakness of 
presumptive color tests; that their accuracy is based on subjective interpretation.   
5. CONCLUSIONS 
 In this investigation, a thorough literature search was conducted. The goal of 
this literature review was to establish a connection between what is known in the 
medical field regarding a selection of the more deleterious adulterants found in 
forensic samples and how this information may assist a forensic pathologist during a 
death investigation.  This topic was approached by asking a question based on the 
structure or functionality of the adulterants to determine what kind of side effects one 
might see as a result of the consumption of these compounds.  Literature research 
was performed to determine if these effects are indeed observed, and finally, the 
information was applied to forensic pathology and death investigation.  The specific 
adulterants investigated were: levamisole, atropine, phenacetin, and the topical 
anesthetics: benzocaine, lidocaine, prilocaine, and procaine. 
 A thorough literature review revealed that levamisole stimulates the immune 
system, inducing the production of antibodies and increasing function of monocytes 
and macrophages.  The immunomodulation results in the production of self-reactive 
antibodies, which target surface proteins on neutrophils. This results in a weakened 
immune system, putting the body at risk for infection.  The circulation of self-reactive 
antibodies also ultimately results in vasculitis and a necrotic purpuric rash. Atropine 
functions as a muscarinic antagonist, preventing the function of the neurotransmitter 
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acetylcholine.  This decreases the parasympathetic tone and increases the 
sympathetic tone on the body.  Cocaine is a sympathomimetic amine, meaning it 
acts on the nervous system in a manner which mimics the effects of the sympathetic 
nervous system. Since both function to increase the tone of the sympathetic nervous 
system, the presentation of a cocaine overdose can appear very similar to an 
overdose of atropine. Review of the literature revealed that cocaine overdose causes 
a condition known as sympathomimetic toxidrome while atropine overdose results 
in a condition known as anticholinergic toxicity. The symptoms of both are as 
follows: hypertension, hyperthermia, tachycardia, pupil dilation, ataxia, seizures, 
disorientation, and delirium. The key differences that can be used to distinguish 
between the two are that the mydriasis observed from sympathomimetic toxidrome 
is reactive to light while the pupil dilation will be fixed in the case of anticholinergic 
toxicity.  Sympathomimetic toxidrome typically presents with diaphoresis, or profuse 
sweating, while anticholinergic toxicity exhibits dry, flushed skin. Also, 
anticholinergic toxicity decreases gastrointestinal motility and causes urinary 
retention while sympathomimetic syndrome will exhibit increased bowel motility 
and urinary output.  Phenacetin is an analgesic structurally similar to 
acetaminophen. It acts on the body in a similar manner to reduce pain and fever by 
inhibiting the body’s natural inflammatory response. This drug is known to cause 
papillary necrosis and tumor generation in the bladder and kidneys. A literature 
search revealed that phenacetin is metabolized to O-Et-NAPQI, which is analogous 
to NAPQI, the toxic metabolite of acetaminophen. These compounds are unstable 
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and highly reactive. NAPQI is produced in the liver and is capable of covalently 
binding to proteins and other structural components of hepatic cells. O-Et-NAPQI is 
produced in the bladder and is more reactive than NAPQI. The instability of O-Et-
NAPQI allows it to covalently bind to DNA nucleotides causing mutations and 
tumor generation. The topical anesthetics lidocaine, prilocaine, benzocaine, and 
procaine have all been found to be associated with the development of 
methemoglobinemia. While lidocaine and prilocaine are structurally similar, and 
benzocaine and procaine are structurally similar, the only similarity among all four is 
the presence of an aromatic amine moiety. A review of the literature revealed that 
prilocaine and lidocaine are metabolized to O-toluidine and 2,6-xylidine respectively. 
One article concluded that these compounds are capable of oxidizing ferrous iron to 
ferric iron, suggesting that it is the presence of these compounds in the bloodstream 
which are responsible for the development of methemoglobinemia (49). How 
methemoglobinemia may develop as a result of benzocaine and procaine use has not 
been described previously, however the FDA has released several bulletins and 
warnings of the danger of methemoglobinemia from benzocaine and many case 
reports and discussions are still being published in the literature.  
In addition to the literature based portion of this investigation, the effects 
observed on the Marquis reagent and the modified Scott test of twenty-three 
common adulterants of cocaine and heroin, as well as mixtures thereof, were 
recorded and analyzed.  Based on the data presented here, it can be concluded that 
none of the adulterants or mixtures tested yielded a result that could be considered a 
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false positive when tested at a mass up to 1 mg with either of these tests. However, it 
was observed that the results of the Marquis reagent can be altered when adulterants 
are tested in combination with one another. It was observed that when 
diphenhydramine, a compound highly reactive to the Marquis reagent, was tested in 
combination with other compounds, the results appeared highly dissimilar. 
Additionally, when three compounds which were unreactive with the Marquis 
reagent when tested alone were mixed and tested together, a color change was 
observed.   
The complexity of the modified Scott test makes the test highly specific for 
cocaine. However, the results of this analysis demonstrate that mixtures of 
compounds make the interpretation of the results increasingly difficult. While 
cocaine base or cocaine HCl have characteristic reactions for each step during this 
test, the presence of adulterants may result in hard-to-interpret observations. 
Examples observed in this investigation include blue flecks which persisted from step 
1 to step 2, or a purple color development rather than pink or blue during step 2. 
These results, while not consistent with a presumptively positive identification 
for the target analytes, illustrate the impact the presence of additional compounds in 
a sample can have on presumptive analysis using these methods. This investigation 
has shown that mixtures of compounds can result in color change reactions which do 
not resemble the color observed when tested alone and can cause a color change to 
occur where previously no color development was observed.  Colorimetric spot tests 
have the inherent weakness of relying upon the qualitative assessment of a subjective 
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result for interpretation.  Given the constantly fluctuating trends of street drug purity, 
the interaction of adulterants on presumptive tests needs to be understood by the 
analyst at the risk of misinterpretation.  The potential for ―false negative‖ 
conclusions or misidentification is high. 
6. FUTURE DIRECTIONS 
 Drug adulteration is a common practice among drug dealers and 
manufacturers.  By combining various chemical substances with the drug of abuse 
they intend to sell, they can either enhance or mimic the desired effects of the illicit 
substance and convince their customer they are purchasing a quality product.  
During the research process of this investigation, it was found that there is a notable 
lack of available information.  The NFLIS data was the most comprehensive 
resource available and the purity information provided was limited by the small 
number of reporting laboratories.  Analytically, the forensic chemist is searching for 
the drug of abuse in order to confirm its presence in the sample.  If the drug is 
present, that is usually the end of the analysis.  Using techniques such as Selected Ion 
Monitoring (SIM) during GC/MS analysis, the suspected drug molecule is the only 
molecule that is looked for and has the potential to be the only compound detected in 
the results of an unknown powder cut with adulterants.  This research is an attempt 
to illustrate the impact these adulterants can have on the analysis of forensic samples, 
the pathologist examinations, the health of the user, and the public health of the 
community. 
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 Moving forward, it is important that drug purity information and adulterant 
content become a part of forensic drug analysis.  As eloquently stated in the article 
―Cheese: An old drug in a new wrapper‖ written by Jane C. Maxwell et al. and 
published in 2012 in the journal: Drug and Alcohol Dependence, issue 126: ―…there 
are two places where the drug will make its first official presence in the community 
known. The first of these is the local hospital emergency department and the second 
is the office of the local medical examiner.‖ This particular paper was discussing new 
drugs of abuse emerging in a community; however, it equally applies to the addition 
of novel adulterants to street drugs already on the market. If the forensic analyst can 
discover toxic adulterants in seized drug samples in the forensic lab, public 
awareness can be raised and lives can be saved.  
  Throughout the research process, there was a notable lack of accessible 
information on this topic.  There were brief, misinformed news articles warning of 
―flesh-eating cocaine‖ contaminated with levamisole (56), and there were technical 
reports from the DEA released occasionally that were full of technical data and 
analytical information. These reports don’t convey the necessary information to the 
public and do not tell the individual what is going on in their own community.  
Much of what the public may know about drug adulterants may come from urban 
legend or hearsay. One article describes common misconceptions among drug users 
who stated that they believed cocaine was commonly cut with ground glass, 
household cleaners, brick dust and even rat poison (1).  This illustrates the 
misinformation available inundating the public.  Local forensic laboratories should 
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routinely analyze seized samples assessing purity and composition.  A future project 
or such a program may raise public awareness by publishing their results in areas 
around the community, making certain they are informative and accessible to the 
general public.   Making the public aware of what is present in street drugs can be a 
useful deterrent and could potentially cut down on drug abuse. There is no pattern to 
follow or trend to look for when identifying novel adulterants in seized drug samples. 
The people behind the drug market will add any chemical available, if it is cheaper 
than the drug itself, they can profit from cutting it into the product they are selling.  
This is how substances as toxic as levamisole or as carcinogenic as phenacetin end 
up in street drugs. The search for novel adulterants must be vigilant and 
comprehensive. 
 The NFLIS data shows the variability of street drug purity as reported by a 
number of different labs. These data show the relevance of continued investigation 
into drug adulterants and their effects on forensic analysis.  Street drug purity 
fluctuates from year to year but never approaches 100% meaning that the analyst will 
likely never receive a pure sample in a forensic lab.  Given that these adulterants 
have the potential to be anything it is essential that thorough investigations be done 
into how these adulterants, as well as mixtures thereof, affect the various stages of 
forensic analysis. 
 Moving forward in the direction of laboratory investigation, testing should be 
continued analyzing more adulterants, more mixtures, and more colorimetric spot 
tests. There are a number of colorimetric spot tests used in forensic chemistry 
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analysis and this research could be extended to each of them.  Also, an investigation 
into how each of the compounds and mixtures react while in the presence of the 
target analytes would provide information which could help analysts better 
understand the impact these adulterants have on the interpretation of analytical 
results.  
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